Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Strong Q2: Why the Volpara (ASX:VHT) share price is rising

The Volpara Health Technologies Ltd (ASX:VHT) share price is rising after the company released its FY22 second quarter.

The Volpara Health Technologies Ltd (ASX: VHT) share price is rising after the company released its FY22 second quarter.

FY22 second quarter

The healthcare business said that it delivered record quarterly growth in net new annual recurring revenue (ARR), adding US$1.2 million, which has historically been the slowest quarter.

Volpara closed its largest contract to date, that will deliver US$2.15 million of revenue over five years, being US$430,000 in ARR.

This brings the company’s ARR to around US$20.4 million, or NZ$29 million. That’s an increase of around 10% since the end of the FY21.

Looking at its market share, Volpara estimates that it now has at least one software product contracted to be used in the breast screening of approximately 34% of US women, equal to approximately 13.4 million women.

Volpara’s average revenue per user (ARPU) was US$2.04 for the quarter, and is now US$1.46 over the entire installed base, up from US$1.42 in the first quarter of FY22.

Other highlights included entering into collaboration agreements with lung cancer AI leaders Riverain and RevealDX and a genetics collaboration agreement with Natera.

Positive trends

Volpara said that the prevailing trend of Volpara’s customer base is their desire to facilitate personalised breast cancer care with tightly integrated breast density, cancer risk and patient reporting.

A key part of the potential growth of Volpara is increasing its ARPU by upselling to existing customers.

The healthcare business said that it expanded two large existing Analytics customers by US$70,000 and US$35,000 respectively, taking both their contracts to approximately US$250,000 per annum.

There was an expansion of another large Analytics customer to Patient Hub, Risk and Scorecard, increasing ARR by another US$132,000 to over US$200,000 at an ARPU of US$6.37.

Finally, multiple patient hub upgrades were seen moving away from MRS 7 or MRS 6 onto multi-year software as a service (SaaS) contracts.

Thoughts on Volpara and the share price

The company said it is entering the third quarter with a strong pipeline and is looking forward to presenting at RSNA, the world’s largest radiology trade show in early December.

I think Volpara is one of the ASX growth shares to watch, particularly with the fast level of progress it’s seeing and the encouraging signs of upgrading customers. I’d consider it at today’s level.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content